Plain-language summary

This Phase 2 trial is studying reduced-intensity radiotherapy for people with NK/T-cell lymphoma. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

Who can join (key eligibility)

• Age 18 Years to 75 Years years
• Must be well enough for treatment (adequate performance status)

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

reduced-intensity radiotherapy (RADIATION): The patients will receive radiotherapy. The target volume, determined based on the involvement of the primary tumor and sites of metastasis, will include the nasal cavity or Waldeyer's ring, with or without bilateral cervical lymphatic drainage areas. The prescribed dose is 45 Gy in 25 fractions, at 1.8 Gy per fraction per day, five days per week, to be completed within five weeks.

Drugs / treatments

reduced-intensity radiotherapy

Treatment length

Ask the trial team for details

Visit frequency

Ask the trial team for details